试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2018-01-08
Study to Evaluate the Safety and EffIcacy of PRX-102 on Gastrointestinal Symptoms in Naïve Fabry Disease
编号:NCT02921620登记状态:入组前撤回企业 / 申办者:Protalix
药物 / 成分:PRX-102、Placebo
登记的停止原因(原文):Protocol not feasible
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2018-01-05
Bone Marrow-derived Mesenchymal Stem Cells (MSC) Administration in Weaning From Left Ventricular Assist Device
编号:NCT02460770登记状态:入组前撤回企业 / 申办者:University Hospital, Toulouse
药物 / 成分:Autologous mesenchymal stem cells
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2018-01-04
Fentanyl Sublingual Spray for the Treatment of Acute Procedure-related Pain in a Monitored Setting
编号:NCT02138409登记状态:入组前撤回企业 / 申办者:INSYS Therapeutics Inc
药物 / 成分:Fentanyl Sublingual Spray (FSS)、Placebo Sublingual Spray (PSS)
登记的停止原因(原文):Sponsor elected not to continue with study.
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2018-01-04
Cannabidiol Oral Solution as an Adjunctive Therapy for Treatment of Participants With Inadequately Controlled Lennox-Gastaut Syndrome
编号:NCT02318537登记状态:入组前撤回企业 / 申办者:INSYS Therapeutics Inc
药物 / 成分:Cannabidiol Oral Solution、Placebo Solution
登记的停止原因(原文):Sponsor elected not to continue with study.
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2018-01-04
Cannabidiol Oral Solution as an Adjunctive Therapy for Treatment of Participants With Inadequately Controlled Dravet Syndrome
编号:NCT02318563登记状态:入组前撤回企业 / 申办者:INSYS Therapeutics Inc
药物 / 成分:Cannabidiol Oral Solution、Placebo Solution
登记的停止原因(原文):Sponsor elected not to continue with study.
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2018-01-04
A Study of Epacadostat + Pembrolizumab in Head and Neck Cancer Patients, Who Failed Prior PD-1/PD-L1 Therapy
编号:NCT03238638登记状态:入组前撤回企业 / 申办者:University of Chicago
药物 / 成分:Pembrolizumab、epacadostat
登记的停止原因(原文):PI did not attempt to open the study.
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2017-12-29
Phase II Study of Simvastatin for Relapsed/Refractory Myeloma
编号:NCT01332617登记状态:入组前撤回企业 / 申办者:University of Louisville
药物 / 成分:Simvastatin,Zoledronic Acid,Bortezomib,Bendamustine,Methylprednisolone.
登记的停止原因(原文):Investigators no longer interested in activating study
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2017-12-29
Pre-operative Mocetinostat (MGCD0103) and Durvalumab (MEDI4736) (PRIMED) for Squamous Cell Carcinoma of the Oral Cavity
编号:NCT02993991登记状态:入组前撤回企业 / 申办者:University Health Network, Toronto
药物 / 成分:Mocetinostat、Durvalumab
登记的停止原因(原文):The study has been terminated due to a change in internal prioritization and not due to any safety concerns.
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2017-12-29
TAU PET Imaging in Northern Manhattan Study of Metabolism and Mind
编号:NCT03024944登记状态:入组前撤回企业 / 申办者:Columbia University
药物 / 成分:18F-THK-5351
登记的停止原因(原文):18F-THK5351 was reported non-specific binding of MAO receptors.
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2017-12-26
Pilot Study About Safety and Efficacy of Atomized Intrapleural Lidocaine During Pleuroscopy
编号:NCT00693043登记状态:入组前撤回企业 / 申办者:Lahey Clinic
药物 / 成分:lidocaine hydrochloride
登记的停止原因(原文):Principal Investigator left the institution requested termination
查看官方原始记录 ↗